房颤患者使用地尔硫䓬联合阿哌沙班或利伐沙班的严重出血风险
该回顾性队列纳入2012年1月1日至2020年11月29日启动阿哌沙班或利伐沙班、并同时开始地尔硫䓬或美托洛尔治疗的65岁及以上美国医保房颤患者204155例(地尔硫䓬53275例、美托洛尔150880例),随访至365天。主要终点为出血相关住院与近期有出血证据的死亡的复合终点,地尔硫䓬组风险高于美托洛尔组(RD 10.6/1000人年,95%CI 7.0-14.2;HR 1.21,95%CI 1.13-1.29)。地尔硫䓬初始剂量>120 mg/d者主要终点风险(HR 1.29,95%CI 1.19-1.39)高于较低剂量者(HR 1.13,95%CI 1.04-1.24)。作者结论认为,在接受阿哌沙班或利伐沙班的房颤患者中,地尔硫䓬与比美托洛尔更高的严重出血风险相关,尤其是地尔硫䓬剂量>120 mg/d时。
要点
- 主要终点为出血相关住院与近期有出血证据的死亡的复合终点,地尔硫䓬组高于美托洛尔组:RD 10.6/1000人年(95%CI 7.0-14.2),HR 1.21(95%CI 1.13-1.29)。
- 出血相关住院:地尔硫䓬组 RD 8.2/1000人年(95%CI 5.1-11.4),HR 1.22(95%CI 1.13-1.31);近期有出血证据的死亡:RD 2.4/1000人年(95%CI 0.6-4.2),HR 1.19(95%CI 1.05-1.34)。
- 地尔硫䓬初始剂量>120 mg/d者主要终点 RD 15.1/1000人年(95%CI 10.2-20.1)、HR 1.29(95%CI 1.19-1.39),高于较低剂量者的 RD 6.7/1000人年(95%CI 2.0-11.4)、HR 1.13(95%CI 1.04-1.24)。
- 高剂量与低剂量地尔硫䓬直接比较,主要终点 HR 1.14(95%CI 1.02-1.26);剂量>120 mg/d者主要缺血或出血事件风险升高(HR 1.14,95%CI 1.02-1.27)。
- 两个剂量组缺血性卒中或系统性栓塞、无近期出血证据的死亡风险均无显著变化。
适用人群与场景
- 美国医保(Medicare)受益人中年龄65岁及以上、患有心房颤动、启动阿哌沙班或利伐沙班治疗,并在2012年1月1日至2020年11月29日期间同时开始地尔硫䓬或美托洛尔治疗的患者。
- 随访至365天,截至2020年11月30日;共204155例,其中地尔硫䓬组53275例、美托洛尔组150880例;平均(SD)年龄76.9(7.0)岁,女性占52.7%;随访90927人年,中位随访120天(IQR 59-281天)。
研究设计与关键结果
- 研究类型:回顾性队列研究;人群:65岁及以上美国医保房颤患者,启动阿哌沙班或利伐沙班并同时开始地尔硫䓬(53275例)或美托洛尔(150880例)治疗,共204155例。
- 主要终点(出血相关住院与近期有出血证据的死亡的复合终点):地尔硫䓬组高于美托洛尔组,RD 10.6/1000人年(95%CI 7.0-14.2),HR 1.21(95%CI 1.13-1.29)。
- 出血相关住院:地尔硫䓬组 RD 8.2/1000人年(95%CI 5.1-11.4),HR 1.22(95%CI 1.13-1.31);近期有出血证据的死亡:RD 2.4/1000人年(95%CI 0.6-4.2),HR 1.19(95%CI 1.05-1.34)。
- 地尔硫䓬初始剂量>120 mg/d者主要终点 RD 15.1/1000人年(95%CI 10.2-20.1)、HR 1.29(95%CI 1.19-1.39),高于较低剂量者的 RD 6.7/1000人年(95%CI 2.0-11.4)、HR 1.13(95%CI 1.04-1.24)。
- 剂量>120 mg/d者主要缺血或出血事件风险升高(HR 1.14,95%CI 1.02-1.27);高剂量与低剂量地尔硫䓬直接比较,主要终点 HR 1.14(95%CI 1.02-1.26)。
- 两个剂量组缺血性卒中或系统性栓塞、无近期出血证据的死亡风险均无显著变化。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在接受阿哌沙班或利伐沙班的房颤患者中,地尔硫䓬与比美托洛尔更高的严重出血风险相关,尤其是地尔硫䓬剂量>120 mg/d时。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Diltiazem, a commonly prescribed ventricular rate-control medication for patients with atrial fibrillation, inhibits apixaban and rivaroxaban elimination, possibly causing overanticoagulation.
OBJECTIVE: To compare serious bleeding risk for new users of apixaban or rivaroxaban with atrial fibrillation treated with diltiazem or metoprolol.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included Medicare beneficiaries aged 65 years or older with atrial fibrillation who initiated apixaban or rivaroxaban use and also began treatment with diltiazem or metoprolol between January 1, 2012, and November 29, 2020. Patients were followed up to 365 days through November 30, 2020. Data were analyzed from August 2023 to February 2024.
EXPOSURES: Diltiazem and metoprolol.
MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of bleeding-related hospitalization and death with recent evidence of bleeding. Secondary outcomes were ischemic stroke or systemic embolism, major ischemic or hemorrhagic events (ischemic stroke, systemic embolism, intracranial or fatal extracranial bleeding, or death with recent evidence of bleeding), and death without recent evidence of bleeding. Hazard ratios (HRs) and rate differences (RDs) were adjusted for covariate differences with overlap weighting.
RESULTS: The study included 204 155 US Medicare beneficiaries, of whom 53 275 received diltiazem and 150 880 received metoprolol. Study patients (mean [SD] age, 76.9 [7.0] years; 52.7% female) had 90 927 person-years (PY) of follow-up (median, 120 [IQR, 59-281] days). Patients receiving diltiazem treatment had increased risk for the primary outcome (RD, 10.6 [95% CI, 7.0-14.2] per 1000 PY; HR, 1.21 [95% CI, 1.13-1.29]) and its components of bleeding-related hospitalization (RD, 8.2 [95% CI, 5.1-11.4] per 1000 PY; HR, 1.22 [95% CI, 1.13-1.31]) and death with recent evidence of bleeding (RD, 2.4 [95% CI, 0.6-4.2] per 1000 PY; HR, 1.19 [95% CI, 1.05-1.34]) compared with patients receiving metoprolol. Risk for the primary outcome with initial diltiazem doses exceeding 120 mg/d (RD, 15.1 [95% CI, 10.2-20.1] per 1000 PY; HR, 1.29 [95% CI, 1.19-1.39]) was greater than that for lower doses (RD, 6.7 [95% CI, 2.0-11.4] per 1000 PY; HR, 1.13 [95% CI, 1.04-1.24]). For doses exceeding 120 mg/d, the risk of major ischemic or hemorrhagic events was increased (HR, 1.14 [95% CI, 1.02-1.27]). Neither dose group had significant changes in the risk for ischemic stroke or systemic embolism or death without recent evidence of bleeding. When patients receiving high- and low-dose diltiazem treatment were directly compared, the HR for the primary outcome was 1.14 (95% CI, 1.02-1.26).
CONCLUSIONS AND RELEVANCE: In Medicare patients with atrial fibrillation receiving apixaban or rivaroxaban, diltiazem was associated with greater risk of serious bleeding than metoprolol, particularly for diltiazem doses exceeding 120 mg/d.
参考来源
- Ray WA, Chung CP, Stein CM, et al. Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban. JAMA. 2024. PMID: 38619832. doi:10.1001/jama.2024.3867
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。